Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Helix Biopharma Corp. (HBPCF) had Return on Tangible Equity of 18.14% for the most recently reported fiscal quarter, ending 2026-04-30.
| Income Statement Financials | |
-- |
|
$-0.49M |
|
-- |
|
-- |
|
$0.50M |
|
$-0.50M |
|
$0.01M |
|
$-0.49M |
|
$-0.49M |
|
$-0.49M |
|
$-0.49M |
|
$-0.49M |
|
$-0.49M |
|
$-0.50M |
|
$-0.50M |
|
76.38M |
|
76.38M |
|
$-0.01 |
|
$-0.01 |
|
| Balance Sheet Financials | |
$2.18M |
|
$0.00M |
|
$13.41M |
|
$15.59M |
|
$4.88M |
|
-- |
|
-- |
|
$4.88M |
|
$10.71M |
|
$-2.70M |
|
$10.71M |
|
76.38M |
|
| Cash Flow Statement Financials | |
$-1.86M |
|
-- |
|
$3.88M |
|
$0.05M |
|
$2.06M |
|
$2.01M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.45 |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.86M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-4.57% |
|
|
Return on Tangible Equity |
18.14% |
-3.14% |
|
-4.57% |
|
$0.14 |
|
$-0.02 |
|
$-0.02 |
|